0
Pharmacotherapeutics: Pharmacotherapuetics |

Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD

Yuhua Ji, PhD; Craig Husfeld, PhD; M. Teresa Pulido-Rios, BS; Alexander McNamara, MS; Glenmar P. Obedencio, BS; Mike Baldwin, PhD; David Bourdet, PhD; Sharath Hegde, PhD; Mathai Mammen, MD; Edmund Moran, PhD
Author and Funding Information

Theravance Biopharma US, Inc, South San Francisco, CA


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):970A. doi:10.1016/j.chest.2016.08.1074
Text Size: A A A
Published online

Extract

SESSION TITLE: Pharmacotherapuetics

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Translation of inhalation-by-design drug discovery to late-stage development remains a challenge. Herein, we report a preclinical “duration-by-design” program with the goal to identify a long-acting muscarinic antagonist with structural/pharmacological features ideally suited for once-daily (QD) nebulized delivery.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
COPD therapy: if two is good, is three better? Lancet 2016;388(10048):937-8.
Muscarinic Receptor Antagonists. Handb Exp Pharmacol Published online Oct 28, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543